DE60126134D1 - Crf-rezeptorantagonisten und diese betreffende verfahren - Google Patents

Crf-rezeptorantagonisten und diese betreffende verfahren

Info

Publication number
DE60126134D1
DE60126134D1 DE60126134T DE60126134T DE60126134D1 DE 60126134 D1 DE60126134 D1 DE 60126134D1 DE 60126134 T DE60126134 T DE 60126134T DE 60126134 T DE60126134 T DE 60126134T DE 60126134 D1 DE60126134 D1 DE 60126134D1
Authority
DE
Germany
Prior art keywords
methods
receptor antagonists
crf receptor
crf
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60126134T
Other languages
English (en)
Other versions
DE60126134T2 (de
Inventor
Mustapha Haddach
C Lanier
Q Huang
R Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Application granted granted Critical
Publication of DE60126134D1 publication Critical patent/DE60126134D1/de
Publication of DE60126134T2 publication Critical patent/DE60126134T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60126134T 2000-11-03 2001-11-02 CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen Expired - Fee Related DE60126134T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24582100P 2000-11-03 2000-11-03
US245821P 2000-11-03
PCT/US2001/047919 WO2002040480A2 (en) 2000-11-03 2001-11-02 Crf receptor antagonists and methods relating thereto

Publications (2)

Publication Number Publication Date
DE60126134D1 true DE60126134D1 (de) 2007-03-08
DE60126134T2 DE60126134T2 (de) 2007-10-18

Family

ID=22928212

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60126134T Expired - Fee Related DE60126134T2 (de) 2000-11-03 2001-11-02 CRF-Rezeptorantagonisten und Verfahren, die damit in Beziehung stehen

Country Status (11)

Country Link
US (2) US6747034B2 (de)
EP (1) EP1341793B1 (de)
JP (1) JP2004529075A (de)
KR (1) KR20030060927A (de)
AU (2) AU2002239589B2 (de)
CA (1) CA2427656A1 (de)
DE (1) DE60126134T2 (de)
ES (1) ES2279835T3 (de)
MX (1) MXPA03003714A (de)
NO (1) NO20031997D0 (de)
WO (1) WO2002040480A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7273871B2 (en) * 2001-07-17 2007-09-25 Sb Pharmco Puerto Rico Inc. Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists
PL377847A1 (pl) 2003-01-14 2006-02-20 Arena Pharmaceuticals Inc. 1,2,3-Tripodstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu oraz profilaktyka i leczenie związanych z nim zaburzeń takich jak cukrzyca i hiperglikemia
AU2004247418B2 (en) * 2003-06-10 2009-11-05 F. Hoffmann-La Roche Ag 1.3.4-triaza-phenalene and 1,3,4,6-tetraazaphenalene derivatives
EA010023B1 (ru) 2003-07-14 2008-06-30 Арена Фармасьютикалз, Инк. Конденсированные арильные и гетероарильные производные в качестве модуляторов метаболизма и для профилактики и лечения расстройств, связанных с нарушением метаболизма
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
WO2005063749A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
WO2006031322A2 (en) * 2004-08-09 2006-03-23 Research Development Foundation Determination of the 3d-structure of an extracellular domain of a b1 g-protein coupled receptor by nmr analysis
WO2006081522A2 (en) * 2005-01-26 2006-08-03 The Regents Of The Unversity Of California Modulation of nmda receptor currents via orexin receptor and/or crf receptor
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010080402A (ko) * 1998-11-12 2001-08-22 추후기재 Ｃｒｆ 수용체 길항제 및 그와 관련된 방법
JP2002529465A (ja) * 1998-11-12 2002-09-10 ニューロクライン バイオサイエンシーズ， インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびｃｒｆレセプターアンタゴニストに関する方法

Also Published As

Publication number Publication date
NO20031997L (no) 2003-05-02
AU2002239589B2 (en) 2005-04-21
CA2427656A1 (en) 2002-05-23
US6747034B2 (en) 2004-06-08
MXPA03003714A (es) 2004-05-04
WO2002040480A3 (en) 2003-05-15
EP1341793B1 (de) 2007-01-17
US20040266799A1 (en) 2004-12-30
US20020151557A1 (en) 2002-10-17
AU3958902A (en) 2002-05-27
NO20031997D0 (no) 2003-05-02
EP1341793A2 (de) 2003-09-10
KR20030060927A (ko) 2003-07-16
DE60126134T2 (de) 2007-10-18
ES2279835T3 (es) 2007-09-01
JP2004529075A (ja) 2004-09-24
WO2002040480A2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
ATE368018T1 (de) Gipszusammensetzungen und dazugehörende verfahren
EE200300325A (et) Asendatud amiini derivaadid ning nende kasutamismeetodid
DE60222546D1 (de) Oxidative halogenierung von c1 kohlenwasserstoffen zu halogenierten c1 kohlenwasserstoffen und integriertes verfahren die sich darauf beziehen
DE60003250D1 (de) Reinigungszusammensetzungen und Verfahren zur Reinigung
DE60206653D1 (de) Flammwidrige harzzusammensetzungen und verfahren
DE60232478D1 (de) Nonstopgebührenerfassungssystem und Verfahren
DE60223757D1 (de) Buchbindevorrichtung und Verfahren
ATE452540T1 (de) Zusammensetzung und verfahren
DE60126134D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
IS8526A (is) CRF viðtakamótlyf og aðferðir tengdar þeim
DE60131219D1 (de) Spieldienstbereitstellungeinrichtung und Verfahren
PT1250321E (pt) Composicao de gliburida
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60129570D1 (de) Tastsonde und Verfahren zu deren Zusammensetzung
FR2824827B1 (fr) Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
EE200400042A (et) 8/17 heterotsüklilised ühendid ning nende kasutamine D-alanüül-D-alaniini ligaasi inhibiitoritena
EE200200547A (et) Neovaskularisatsiooni parendatud ravi
DE60134283D1 (de) Dokumentzuführvorrichtung und Verfahren
DK1309323T3 (da) Fremgangsmåde til behandling af angiogeneserelaterede lidelser
NO20030978L (no) Behandling av urindysfunksjon
PT1448566E (pt) Antagonistas do receptor quimioquina e metodos de utilizacao do mesmo
NO20032156D0 (no) Behandling av angstforstyrrelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee